Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/12941
DC FieldValueLanguage
dc.contributor.authorGrozdanova, Aleksandraen_US
dc.contributor.authorHalimi Vesaen_US
dc.contributor.authorZaheer-Ud-Din Babaren_US
dc.contributor.authorArmond Dacien_US
dc.contributor.authorKaterina Ancevska Netkovskaen_US
dc.contributor.authorLjubica Suturkovaen_US
dc.date.accessioned2021-05-31T12:21:17Z-
dc.date.available2021-05-31T12:21:17Z-
dc.date.issued2020-08-03-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/12941-
dc.language.isoenen_US
dc.publisherInt. J. Environ. Res. Public Healthen_US
dc.relation.ispartofInt. J. Environ. Res. Public Healthen_US
dc.subjectbiosimilars; clinical practice; interchangeability; extrapolation; pharmacovigilance; regulatory; knowledge; confidence; educationen_US
dc.titleClinical and Regulatory Concerns of Biosimilars: A Review of Literatureen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.3390/ijerph17165800-
item.fulltextWith Fulltext-
item.grantfulltextopen-
crisitem.author.deptFaculty of Pharmacy-
Appears in Collections:Faculty of Pharmacy: Journal Articles
Files in This Item:
File Опис SizeFormat 
ijerph-17-05800 (3).pdf476.13 kBAdobe PDFView/Open
Прикажи едноставен запис

Page view(s)

39
checked on 18.9.2023

Download(s)

50
checked on 18.9.2023

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.